Kalaris Therapeutics names Liisa Bayko as chief financial officer

Kalaris Therapeutics, Inc. said its board appointed Liisa Bayko as Chief Financial Officer and Treasurer of the Company, effective as of July 20, 2026.¹ She will also serve as the company's principal financial officer.¹

Before joining Kalaris, Bayko, age 55, worked as Managing Director in biotech equity research at investment bank Evercore ISI from August 2020 to December 2025.¹ Earlier in her career, she held the same title, Managing Director in biotech equity research, at investment bank JMP Securities from February 2011 to August 2020.¹ Her academic background includes an MBA from the Kellogg School of Management at Northwestern University, a master of science degree from the University of Toronto, and a bachelor of science degree from Queen's University.¹

Under her employment agreement dated July 7, 2026, Bayko will receive an annualized base salary of $475,000 and will be eligible for an annual bonus of up to 40.0% of that salary.¹ The company also granted her a stock option to purchase up to 220,000 shares, priced at the closing price on her effective date and vesting 25% after one year with the remainder in 36 monthly installments.¹ Severance terms provide for nine months of salary and COBRA premium continuation if she is terminated without cause outside a defined change-in-control window¹, or 12 months of salary, a lump-sum bonus payment, 12 months of COBRA support, and full acceleration of unvested time-based equity if terminated in connection with a change in control.¹

Separately, Brett Hagen notified the company on July 14, 2026 of his resignation as Senior Vice President, Finance and Chief Accounting Officer, effective July 27, 2026.¹ The board then designated Amy Vandekop, the company's Corporate Controller, as interim principal accounting officer effective the same date.¹ Vandekop, age 37, has served as Associate Vice President, Corporate Controller since March 2025 following the merger with AlloVir, Inc., and previously held accounting roles at AlloVir and Lumicell, Inc.¹